Foghorn Therapeutics announces first patient dosed with FHD-909 in Phase 1 trial for SMARCA4 mutated cancers

Foghorn Therapeutics Inc.

First patient dosed with FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor, in Phase 1 trial for SMARCA4 mutated solid tumors.
Primary target patient population is non-small cell lung cancer (NSCLC).
Lilly leads clinical development under a U.S. 50/50 co-development and co-commercialization collaboration with Foghorn.
Preclinical studies showed robust anti-tumor monotherapy activity and favorable tolerability in SMARCA2 mutant xenograft models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.